The drug, Wegovy, uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make ...
Weight loss jabs like Ozempic cuts risk of heart attack and stroke by fifth, ‘game-changing’ study finds - Risk of serious ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
Find your bookmarks in your Independent Premium section, under my profile Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has ...
The weight loss jab has become a blockbuster pharmaceutical hit, with people, including the diabetics it was originally ...
A groundbreaking study has revealed that an anti-obesity jab containing semaglutide, a drug used to treat obesity, significantly reduces the risk of heart attacks and strokes, regardless of the ...
A weight loss injection could reduce the risk of heart attacks and benefit the cardiovascular health of adults, according to a study on what could be the largest medical breakthrough since statins.
Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an analysis of a study funded by a drug manufacturer. Researchers looked ...
An anti-obesity drug could have additional health benefits including reducing the risk of heart attacks and strokes a new study has revealed. A five-year study was carried out by a team led ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three years of treatment, according to an analysis of data from the five-year ...